Miura Global Management Trimmed Accelerate Diagnostics (AXDX) Stake by $2.20 Million; Stock Price Declined; Oppenheimer Asset Management Cut Its Position in Northrop Grumman (NOC) by $818,844 as Stock Value Declined

June 7, 2018 - By Ash

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Logo

Pasco Alfaro / Richard Tumure decreased its stake in Accelerate Diagnostics Inc (AXDX) by 33.33% based on its latest 2018Q1 regulatory filing with the SEC. Miura Global Management Llc sold 100,000 shares as the company’s stock declined 23.87% with the market. The hedge fund run by Pasco Alfaro / Richard Tumure held 200,000 shares of the capital goods company at the end of 2018Q1, valued at $4.57 million, down from 300,000 at the end of the previous reported quarter. Miura Global Management Llc who had been investing in Accelerate Diagnostics Inc for a number of months, seems to be less bullish one the $1.11 billion market cap company. The stock decreased 1.68% or $0.35 during the last trading session, reaching $20.5. About 182,481 shares traded. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) has declined 29.70% since June 7, 2017 and is downtrending. It has underperformed by 42.27% the S&P500. Some Historical AXDX News: 09/05/2018 – ACCELERATE DIAGNOSTICS 1Q LOSS/SHR 37C, EST. LOSS/SHR 32C; 21/04/2018 – Accelerate Diagnostics announces sizeable release of new data at ECCMID 2018; 22/03/2018 Accelerate Diagnostics Inc. Announces $150 Million Convertible Notes Offering; 30/04/2018 – Accelerate Diagnostics to Review First Quarter 2018 Results on May 9th; 24/04/2018 – Accelerate Diagnostics Forms Golden Cross: Technicals; 26/04/2018 – FDA: Accelerate Diagnostics Inc- Accelerate PhenoTest BC kit, Ref #10101018. The firm name on the label is Accelerate; 23/03/2018 – ACCELERATE DIAGNOSTICS INC – SALE OF NOTES TO INITIAL PURCHASERS EXPECTED TO RESULT IN ABOUT $145.6 MLN IN NET PROCEEDS TO ACCELERATE DIAGNOSTICS; 23/04/2018 – DJ Accelerate Diagnostics Inc, Inst Holders, 1Q 2018 (AXDX); 22/03/2018 – ACCELERATE DIAGNOSTICS INC – EXPECTS TO USE PART OF PROCEEDS OF OFFERING TO PAY PREPAYMENT AMOUNT OF THE PREPAID FORWARD; 09/05/2018 – ACCELERATE DIAGNOSTICS 1Q LOSS/SHR 37C

Oppenheimer Asset Management Inc decreased its stake in Northrop Grumman Corp (NOC) by 16.59% based on its latest 2018Q1 regulatory filing with the SEC. Oppenheimer Asset Management Inc sold 2,353 shares as the company’s stock declined 6.52% with the market. The institutional investor held 11,829 shares of the industrial machinery and components company at the end of 2018Q1, valued at $4.13 million, down from 14,182 at the end of the previous reported quarter. Oppenheimer Asset Management Inc who had been investing in Northrop Grumman Corp for a number of months, seems to be less bullish one the $58.93B market cap company. The stock increased 0.81% or $2.71 during the last trading session, reaching $337.93. About 408,230 shares traded. Northrop Grumman Corporation (NYSE:NOC) has risen 29.40% since June 7, 2017 and is uptrending. It has outperformed by 16.83% the S&P500.

Since February 13, 2018, it had 0 insider buys, and 9 sales for $6.82 million activity. $1.03 million worth of Northrop Grumman Corporation (NYSE:NOC) was sold by Hardesty Michael A. The insider Pamiljans Janis G sold $323,602.

Oppenheimer Asset Management Inc, which manages about $12.85 billion and $3.99 billion US Long portfolio, upped its stake in Realty Income Corp (NYSE:O) by 13,285 shares to 27,922 shares, valued at $1.44 million in 2018Q1, according to the filing. It also increased its holding in Matador Res Co (NYSE:MTDR) by 17,653 shares in the quarter, for a total of 29,998 shares, and has risen its stake in International Business Machs (NYSE:IBM).

Analysts await Northrop Grumman Corporation (NYSE:NOC) to report earnings on July, 25. They expect $3.73 earnings per share, up 18.41% or $0.58 from last year’s $3.15 per share. NOC’s profit will be $650.46 million for 22.65 P/E if the $3.73 EPS becomes a reality. After $4.21 actual earnings per share reported by Northrop Grumman Corporation for the previous quarter, Wall Street now forecasts -11.40% negative EPS growth.

More important recent Northrop Grumman Corporation (NYSE:NOC) news were published by: Prnewswire.com which released: “Ollie’s Bargain Outlet Holdings Set to Join S&P MidCap 400; Berkshire Hills Bancorp Set to Join S&P SmallCap 600” on June 06, 2018, also Seekingalpha.com published article titled: “Wall Street Breakfast: ECB Steps Toward Exiting QE”, Globenewswire.com published: “Northrop Grumman to Webcast Annual Shareholders Meeting” on May 11, 2018. More interesting news about Northrop Grumman Corporation (NYSE:NOC) was released by: Bizjournals.com and their article: “The GSA has prevailed in a court battle over this massive IT contract” with publication date: June 07, 2018.

Investors sentiment decreased to 0.88 in 2018 Q1. Its down 0.10, from 0.98 in 2017Q4. It is negative, as 57 investors sold NOC shares while 306 reduced holdings. 89 funds opened positions while 232 raised stakes. 137.81 million shares or 0.54% more from 137.07 million shares in 2017Q4 were reported. California Pub Employees Retirement Systems holds 396,073 shares or 0.2% of its portfolio. Zeke Cap Lc holds 0.14% or 4,371 shares. Bridgeway Mgmt Inc owns 700 shares. Geode Capital Mgmt Ltd Company reported 0.23% stake. Moreover, Guardian has 0.23% invested in Northrop Grumman Corporation (NYSE:NOC). Cullinan Associates, Kentucky-based fund reported 1,200 shares. Hays Advisory Limited Liability Corporation invested in 9 shares. Moreover, Thrivent For Lutherans has 0.03% invested in Northrop Grumman Corporation (NYSE:NOC) for 26,350 shares. Kentucky Retirement stated it has 9,085 shares. 24,731 were reported by Brinker Cap Inc. Hanseatic reported 2,314 shares. Thomas J Herzfeld Advsrs Inc holds 0% in Northrop Grumman Corporation (NYSE:NOC) or 20 shares. Ls Advsr Ltd Liability Co has invested 0.16% of its portfolio in Northrop Grumman Corporation (NYSE:NOC). 17,322 are owned by Amg Natl Tru Commercial Bank. Goldman Sachs Gru Inc has 0.16% invested in Northrop Grumman Corporation (NYSE:NOC) for 1.75 million shares.

Among 20 analysts covering Northrop Grumman (NYSE:NOC), 13 have Buy rating, 0 Sell and 7 Hold. Therefore 65% are positive. Northrop Grumman had 66 analyst reports since July 30, 2015 according to SRatingsIntel. The stock of Northrop Grumman Corporation (NYSE:NOC) earned “Neutral” rating by Citigroup on Wednesday, March 1. RBC Capital Markets maintained the shares of NOC in report on Monday, August 28 with “Buy” rating. RBC Capital Markets maintained it with “Buy” rating and $41900 target in Friday, April 6 report. The stock has “Equal-Weight” rating by Barclays Capital on Tuesday, February 16. Cowen & Co maintained Northrop Grumman Corporation (NYSE:NOC) rating on Monday, July 17. Cowen & Co has “Hold” rating and $27500 target. The rating was maintained by Argus Research on Friday, August 4 with “Buy”. The company was upgraded on Wednesday, October 28 by Drexel Hamilton. J.P. Morgan upgraded Northrop Grumman Corporation (NYSE:NOC) on Tuesday, December 12 to “Buy” rating. Argus Research maintained the stock with “Buy” rating in Thursday, November 12 report. As per Thursday, October 26, the company rating was maintained by RBC Capital Markets.

Another recent and important Accelerate Diagnostics, Inc. (NASDAQ:AXDX) news was published by Seekingalpha.com which published an article titled: “Premarket analyst action – healthcare” on May 24, 2018.

Since February 20, 2018, it had 7 insider buys, and 0 selling transactions for $4.73 million activity.

Investors sentiment increased to 1.1 in Q1 2018. Its up 0.29, from 0.81 in 2017Q4. It is positive, as 10 investors sold AXDX shares while 29 reduced holdings. 14 funds opened positions while 29 raised stakes. 20.31 million shares or 2.07% more from 19.90 million shares in 2017Q4 were reported. Thompson Inv Management Incorporated reported 0.12% of its portfolio in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Goldman Sachs Grp Incorporated owns 0% invested in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) for 82,085 shares. Tiaa Cref Investment Limited Liability invested in 0% or 63,448 shares. Hightower Advisors Limited Liability Corporation has invested 0% of its portfolio in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Alliancebernstein Ltd Partnership invested 0% of its portfolio in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Next Century Growth Invsts Lc invested in 531,737 shares. Parametric Associates Ltd Liability Corp invested in 0% or 30,644 shares. Vanguard Grp has 0% invested in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). 177,188 are owned by Susquehanna Interest Llp. Cypress Mgmt Limited Liability Company (Wy) holds 0.01% or 211 shares in its portfolio. The New York-based Cannell Peter B And has invested 0.96% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% of its portfolio in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Lord Abbett And Co Ltd invested in 0% or 57,000 shares. Raymond James & Assoc has invested 0% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Blackrock Inc holds 1.68 million shares.

Miura Global Management Llc, which manages about $2.90B and $501.69M US Long portfolio, upped its stake in Asml Holding N V (NASDAQ:ASML) by 98,000 shares to 218,000 shares, valued at $43.29M in 2018Q1, according to the filing. It also increased its holding in Match Group Inc by 115,000 shares in the quarter, for a total of 765,000 shares, and has risen its stake in Interactive Brokers Group In (NASDAQ:IBKR).

Among 5 analysts covering Accelerate Diagnostics (NASDAQ:AXDX), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Accelerate Diagnostics had 10 analyst reports since August 25, 2015 according to SRatingsIntel. BTIG Research upgraded the shares of AXDX in report on Tuesday, August 25 to “Neutral” rating. The stock of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) earned “Neutral” rating by BTIG Research on Wednesday, December 13. The firm has “Buy” rating given on Thursday, August 3 by Piper Jaffray. William Blair initiated the stock with “Outperform” rating in Friday, January 8 report. The rating was maintained by JP Morgan with “Overweight” on Tuesday, August 9. The rating was maintained by Piper Jaffray on Sunday, September 17 with “Buy”. The rating was reinitiated by BTIG Research with “Buy” on Wednesday, July 12. The firm earned “Overweight” rating on Wednesday, December 16 by Piper Jaffray. JP Morgan initiated the shares of AXDX in report on Thursday, March 24 with “Overweight” rating.

Analysts await Accelerate Diagnostics, Inc. (NASDAQ:AXDX) to report earnings on August, 2. They expect $-0.37 earnings per share, down 19.35% or $0.06 from last year’s $-0.31 per share. After $-0.37 actual earnings per share reported by Accelerate Diagnostics, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Northrop Grumman Corporation (NYSE:NOC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>